COMPARING THE EFFICACY AND SAFETY OF RUXOLITINIB IN PATIENTS WITH LOWER AND HIGHER RISK MYELOFIBROSIS: A SINGLE-ARM, EXPLORATORY AND PROSPECTIVE STUDY

EHA Library, Jian Huang, 420114

MYMPNVOICE – THE NEW MPN APP FOR PATIENT REPORTED OUTCOMES AND BIOMETRIC DATA MONITORING

EHA Library, Patrick Harrington, 420115

THE CLINICAL BURDEN OF MYELOFIBROSIS AND ASSOCIATED ANEMIA IN FRANCE

EHA Library, Alexander Slowley, 420116

VARIABLES ASSOCIATED WITH OUTCOMES IN PATIENTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE MYELOPROLIFERATIVE NEOPLASM IN ACCELERATED PHASE/BLAST PHASE

EHA Library, Jiang Qian, 420117

EVALUATION OF THE RISKS OF DEVELOPING SECONDARY CANCERS IN PATIENTS WITH CHRONIC MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Maria Kingsley-Godwin, 420118

A RETROSPECTIVE ANALYSIS OF PACRITINIB TREATMENT OUTCOMES IN MYELOFIBROSIS PATIENTS WITH AND WITHOUT MONOCYTOSIS

EHA Library, John Mascarenhas, 420119

HEALTH-RELATED QUALITY OF LIFE IN ITALIAN PATIENTS WITH PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS COMPARED TO THE GENERAL POPULATION: GIMEMA PROPHECY STUDY

EHA Library, Giovanni Caocci, 420120

PROSPECTIVE REAL-WORLD EVIDENCE OF BRENTUXIMAB VEDOTIN (BV) CONSOLIDATION AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (ASCT) IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA (RR HL)

EHA Library, Astrid Pavlovsky, 420121

ANTI-TIM-3 ANTIBODY TQB2618 IN COMBINATION WITH PENPULIMAB IN RELAPSED OR REFRACTORY CLASSIC HODGKIN LYMPHOMA PREVIOUSLY TREATED WITH PD-1/PD-L1 THERAPY

EHA Library, Tongyu Lin, 420122

BCL-2-POSITIVE TUMOUR CELLS AS PREDICTORS OF THE COURSE OF NODULAR SCLEROSIS CLASSICAL HODGKIN LYMPHOMA

EHA Library, Dmitry Diakonov, 420123

A MODIFIED EORTC H10 (MH10)-BASED APPROACH IN PATIENTS WITH LIMITED-STAGE CLASSICAL HODGKIN LYMPHOMA (LS-CHL): SINGLE CENTER 6-YEAR EXPERIENCE WITH FOCUS TO YOUNGER PATIENTS

EHA Library, Theodoros Vassilakopoulos, 420124

PREDICTIVE FACTORS OF AUTOLOGOUS STEM CELL TRANSPLANTATION OUTCOMES AFTER ANTI-PD-1 TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA

EHA Library, Nikita Mochkin, 420125

COFORMULATED VIBOSTOLIMAB/PEMBROLIZUMAB IN RELAPSED/REFRACTORY CHL AND PMBCL: AN ANALYSIS OF COHORTS A AND B OF THE KEYVIBE-004 STUDY

EHA Library, David Lavie, 420126

SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS AND CLINICAL ACTIVITY OF KT-333, A TARGETED PROTEIN DEGRADER OF STAT3, IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC AND SOLID TUMOR CANCERS

EHA Library, Aditi Shastri, 420127

BRENTUXIMAB VEDOTIN AND BENDAMUSTINE FOR RELAPSED HODGKIN LYMPHOMA: HIGH CMR RATE AND MANAGEABLE TOXICITY

EHA Library, Zin Aung Soe, 420128

BRENTUXIMAB VEDOTIN IN COMBINATION WITH BEGEV IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN'S LYMPHOMA: 3-YEAR FOLLOW-UP.

EHA Library, Matvey Bulusov, 420129

CHANGES IN SURVIVAL OF PATIENTS WITH HODGKIN'S LYMPHOMA OVER THE LAST FOUR DECADES

EHA Library, Zsófia Miltényi, 420130

ODRONEXTAMAB MONOTHERAPY FOR RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) AND DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): CLINICAL PHARMACOLOGY AND PHARMACOMETRICS IN THE ELM-1 AND ELM-2 STUDIES

EHA Library, Raul Cordoba, 420131

REAL-WORLD ADHERENCE AND HEALTHCARE RESOURCE UTILIZATION OF BRUTON TYROSINE KINASE INHIBITORS (BTKI) IN MANTLE CELL LYMPHOMA

EHA Library, Bijal D. Shah, 420132

HIGH DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION AS SALVAGE TREATMENT FOR RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA IN THE RITUXIMAB ERA: A RETROSPECTIVE, SINGLE-CENTER ANALYSIS

EHA Library, Silvia Ferrari, 420133

MINIMAL RESIDUAL DISEASE MONITORING IN PATIENTS WITH FOLLICULAR LYMPHOMA AFTER HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANTATION: RESULT FROM FL-015 TRIAL.

EHA Library, Anna Smolyaninova, 420134

SIGNIFICANCE STUDY OF PET/CT IMAGING EVALUATION IN MUCOSA-ASSOCIATED LYMPHOID TISSUE LYMPHOMA

EHA Library, Qingyang Zhang, 420135

THE RESULTS OF FRONTLINE INDUCTION IMMUNOCHEMOTHERAPY WITH R-GEMOX IN MANTLE CELL LYMPHOMA: A GOOD BALANCE BETWEEN EFFICACY AND SAFETY

EHA Library, Antonio Gutiérrez, 420136

RETROSPECTIVE ANALYSIS OF INFECTIOUS EVENTS IN LYMPHOMA PATIENTS WHO WERE TREATED WITH BENDAMUSTINE PLUS ANTI-CD20 MONOCLONAL ANTIBODY: KOREAN, MULTICENTER STUDY

EHA Library, Jun Ho Yi, 420137

THE CLINICAL CHARACTERISTICS AND PROGNOSIS OF FOLLICULAR LYMPHOMA GRADE 3A

EHA Library, Wenjuan Yu, 420138

FACTORS OF FAILURE OF THE MAIN 1ST-LINE IMMUNOCHEMOTHERAPY REGIMENS IN PATIENTS WITH FOLLICULAR LYMPHOMA: DATA FROM A TWO-CENTER STUDY

EHA Library, Evgenii Kunevich, 420139

REAL WORLD SAFETY AND EFFICACY DATA FOR USE OF RITUXIMAB AND BENDAMUSTINE (BR) IN TREATMENT OF ELDERLY AND OR UNFIT PATIENTS WITH MANTLE CELL LYMPHOMA

EHA Library, Sujeet Kumar, 420140

RESULTS FROM A PHASE 1 DOSE ESCALATION STUDY OF HMPL-760, A THIRD GENERATION, HIGHLY SELECTIVE, REVERSIBLE BTK INHIBITOR IN CHINESE PATIENTS WITH RELAPSED/REFRACTORY (R/R) LYMPHOMAS

EHA Library, Ying Qian, 420141

LONG-TERM SURVIVAL OUTCOMES OF 'WATCH AND WAIT' IN PATIENTS WITH BRONCHUS-ASSOCIATED LYMPHOID TISSUE LYMPHOMA: A MULTICENTER REAL-WORLD DATA ANALYSIS IN KOREA

EHA Library, Kunye Kwak, 420142

OBINUTUZUMAB (G) AND CHEMOTHERAPY FOR FRONT-LINE TREATMENT OF FOLLICULAR LYMPHOMA GRADE IIIB (FL GR.3B) OR COMPOSITE FOLLICULAR AND B-LARGE CELL LYMPHOMA (FL/B-LCL)

EHA Library, Neno Živković, 420143

«LONG-TERM RESULTS OF THERAPY FOR PATIENTS WITH MANTLE CELL LYMPHOMA ACCORDING TO THE “MCL-2016” STUDY»

EHA Library, Evgeniy Zvonkov, 420144

INDIRECT COMPARISON OF EFFICACY OF ZANUBRUTINIB VERSUS ACALABRUTINIB IN THE TREATMENT OF RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA

EHA Library, Bijal D. Shah, 420145

MINIMAL RESIDUAL DISEASE (MRD), PHARMACOKINETIC (PK), AND PHARMACODYNAMIC (PD) ASSESSMENT OF EPCORITAMAB 2- VS 3-STEP STEP-UP DOSING IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (R/R FL)

EHA Library, Christopher Morehouse, 420146

MODEL-BASED CYCLE (C) 1 OPTIMIZATION OF STEP-UP DOSE REGIMEN FOR EPCORITAMAB IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)

EHA Library, Kinjal Sanghavi, 420147

TREATMENT OUTCOMES OF BLASTOID-VARIANT MANTLE CELL LYMPHOMA. AN IRISH RETROSPECTIVE MULTI-CENTRE STUDY.

EHA Library, Alfred Jones, 420148

SIMILAR SAFETY PROFILE FOR RITUXIMAB AND OBINUTUZUMAB AS MAINTENANCE FOR FOLLICULAR LYMPHOMA: EVIDENCE FROM A REAL-WORLD MULTICENTER RETROSPECTIVE COHORT STUDY

EHA Library, Ronit Gurion, 420149

THE NUMBER OF CHROMOSOMAL ABERRATIONS IMPACTS SURVIVAL OUTCOMES IN WALDENSTRÖM MACROGLOBULINEMIA: EXPERIENCE FROM A TERTIARY ACADEMIC CENTER

EHA Library, Nicolò Danesin, 420150

CHARACTERIZATION OF WALDENSTRÖM MACROGLOBULINEMIA WITH A FOCUS ON UNUSUAL IMMUNOPHENOTYPES: DIAGNOSTIC CLUES AND POTENTIAL BIOLOGICAL UNDERPINNINGS

EHA Library, Nicolò Danesin, 420151

PROGNOSTIC IMPACT OF GENDER IN NEWLY DIAGNOSED MCL IS ASSOCIATED WITH HIGHER PREVALENCE OF ADVERSE GENETIC EVENTS IN MALES COMPARED TO FEMALES

EHA Library, Diana Malarikova, 420152

FAVEZELIMAB (ANTI-LAG-3) PLUS PEMBROLIZUMAB (PEMBRO) IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) INDOLENT NON-HODGKIN LYMPHOMA: COHORT 4 OF A MULTICOHORT OPEN-LABEL PHASE 1/2 STUDY

EHA Library, David Lavie, 420153

CLINICAL MANIFESTATIONS OF 35 NK CELL LARGE GRANULAR LYMPHOCYTIC LEUKEMIA

EHA Library, Zhe Zhuang, 420154

IMPACT OF EARLY RELAPSE (POD24) & P53 ALTERATIONS ON TREATMENT OUTCOMES IN PATIENTS WITH MCL, MULTI-CENTRE, RETROSPECTIVE COHORT STUDY IN IRELAND.

EHA Library, Ezzat Elhassadi, 420155

THE SAFETY AND EFFICACY OF OBINUTUZUMAB PLUS CHEMOTHERAPY THERAPY FOR UNTREATED FOLLICULAR LYMPHOMA: A CHINESE RETROSPECTIVE ANALYSIS

EHA Library, Zheng Song, 420156

DOSE ADJUSTMENT OUTCOMES IN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA TREATED WITH IBRUTINIB

EHA Library, Shayna Sarosiek, 420157

THE EFFICACY AND SAFETY OF OBINUTUZUMAB WITH ZANUBRUTINIB AS FIRST-LINE TREATMENT IN OLDER PATIENTS WITH MANTLE CELL LYMPHOMA

EHA Library, Yanan Zhu, 420158

IMPACT OF VACCINATION AND CURRENT IMMUNOTHERAPY IN FOLLICULAR LYMPHOMA PATIENTS WITH COVID-19

EHA Library, Mengyuan He, 420159

EVALUATION OF ANEMIA IN NEWLY DIAGNOSED PATIENTS WITH MALIGNANT LYMPHOMAS

EHA Library, Nina Petkova, 420160

ORELABRUTINIB IN PATIENTS WITH INDOLENT NON-HODGKIN LYMPHOMA (INHL) INTOLERANT TO PRIOR BRUTON TYROSINE KINASE INHIBITORS (BTKI): PRELIMINARY RESULTS FROM A PHASE 2 STUDY

EHA Library, Li Wang, 420161

GLOFITAMAB MONOTHERAPY RETREATMENT IN PATIENTS WITH HEAVILY PRETREATED RELAPSED OR REFRACTORY NON-HODGKIN LYMPHOMA: RESULTS FROM A PHASE I/II STUDY

EHA Library, Emmanuel Bachy, 420162

POLATUZUMAB VEDOTIN, ZANUBRUTINIB AND RITUXIMAB (POLA-ZR) ACHIEVED RAPID AND DEEP RESPONSE IN PREVIOUSLY UNTREATED FRAIL AND ELDERLY DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS: UPDATED FOLLOW-UP

EHA Library, Yuhong Ren, 420163

OUTCOMES OF PATIENTS WITH PRIMARY CNS LYMPHOMA TREATED WITH MATRIX CHEMOIMMUNOTHERAPY FOLLOWED BY HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANT – A MULTICENTRE, RETROSPECTIVE STUDY

EHA Library, Adam Suleman, 420164

SIX VS. EIGHT DOSES OF RITUXIMAB IN COMBINATION WITH SIX CYCLES OF CHOP IN PATIENTS WITH NEWLY DIAGNOSED DLBCL

EHA Library, Yoshimasa Kamoda, 420165

CLINICAL AND MOLECULAR CHARACTERISTICS OF PATIENTS WITH DOUBLE/TRIPLE HIT DIFFUSE LARGE B-CELL LYMPHOMA

EHA Library, Yi-ge Shen, 420166

PHASE II STUDY OF EZH2 INHIBITOR TAZEMETOSTAT PLUS AMDIZALISIB, A PI3K INHIBITOR, IN PATIENTS WITH RELAPSED/REFRACTORY LYMPHOMAS

EHA Library, Mingci Cai, 420167

LOGISTICAL CHALLENGES ASSOCIATED WITH CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY (CAR T) IN NON-HODGKIN LYMPHOMA (NHL): A SURVEY OF HEALTHCARE PROFESSIONALS

EHA Library, Anna Sureda Balari, 420168

COMPARISON OF NCCN-IPI VERSUS IPI AS PART OF TRIAL ELIGIBILITY CRITERIA FOR PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA

EHA Library, Jelena Jelicic, 420169

THE EFFICACY AND SAFETY OF BRIDGING CAR-T THERAPY WITH HYPER-FRACTIONATED RADIOTHERAPY IN THE TREATMENT OF RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA

EHA Library, Jing Ruan, 420170

CLINICAL APPLICATION OF AN EX-VIVO PLATFORM TO GUIDE PERSONALIZED SALVAGE THERAPY IN RELAPSED/REFRACTORY MATURED T-CELL AND NK-CELL LYMPHOMAS

EHA Library, Daryl Tan, 420171

NOVEL TARGETED AGENTS IN COMBINATION WITH R-ICE (R-ICE-X) BASED ON GENOTYPING IN RELAPSED/REFRACTORY DLBCL

EHA Library, Yi-ge Shen, 420172

EFFICACY AND SAFETY OF ZANUBRUTINIB COMBINED WITH R-CHOP REGIMEN IN THE TREATMENT OF NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA WITH EXTRANODAL INVOLVEMENT: A PROSPECTIVE PHASE II TRIAL IN CHINA

EHA Library, Tao yang, 420173

FOLLOW-UP ON PHASE 1 STUDY OF AT101, A NOVEL ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR CELL THERAPY (CAR-T) IN RELAPSED OR REFRACTORY (R/R) B-CELL NON-HODGKIN LYMPHOMA PATIENTS

EHA Library, Dok Hyun Yoon, 420174

REAL-WORLD SAFETY OUTCOMES OF AXICABTAGENE CILOLEUCEL IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA AND FOLLICULAR LYMPHOMA IN EUROPE AND UNITED STATES: A SYSTEMATIC REVIEW AND META-ANALYSIS

EHA Library, Robin Sanderson, 420175

THIOTEPA AND POMALIDOMIDE COMBINATION THERAPY FOR RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: PRELIMINARY FINDINGS FROM A PHASE Ⅱ STUDY

EHA Library, Haorui Shen, 420176

SERUM EOTAXIN PREDICTS LONG-TERM SURVIVAL OF R/R AGGRESSIVE B-CELL LYMPHOMA PATIENTS RECEIVING CD19 CAR-T THERAPY

EHA Library, Hu Qian, 420177

A PHASE II, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAFASITAMAB COMBINED WITH LENALIDOMIDE IN PATIENTS WITH RELAPSED/ REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA

EHA Library, Wenjuan Yu, 420178

COMPLETE RESPONSE AT 6 MONTHS IS ASSOCIATED WITH OVERALL SURVIVAL AFTER 1L CHEMOIMMUNOTHERAPY FOR HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA: A POOLED CLINICAL TRIAL ANALYSIS

EHA Library, Ran Reshef, 420179

EPIDEMIOLOGICAL TRENDS AND TREATMENT CHALLENGES OF NON-HODGKIN LYMPHOMA IN ARMENIA: A COMPREHENSIVE RETROSPECTIVE COHORT STUDY

EHA Library, Lusine SAHAKYAN, 420180

GLOFITAMAB EFFICACY, TOLERABILITY, AND PRACTICAL IMPLICATIONS IN THE REAL WORLD: A UK MULTICENTRE, RETROSPECTIVE ANALYSIS.

EHA Library, Kushani Ediriwickrema, 420181

COMBINING BASELINE AND END-OF-TREATMENT QUANTITATIVE PET PARAMETERS TO IMPROVE PROGRESSION-FREE SURVIVAL PREDICTION IN DLBCL

EHA Library, Annelies Bes, 420182

EVALUATING PREDICTORS OF NEW PERSISTENT OPIOID USE IN EARLY SURVIVORSHIP FOR PATIENTS WITH DLBCL

EHA Library, Jessie Peng, 420183

SUBCUTANEOUS CM355, A NOVEL BISPECIFIC CD20/CD3 ANTIBODY SHOWED PROMISING EFFICACY AND FAVORABLE SAFETY PROFILE IN RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA

EHA Library, Chen Zhang, 420184

TISLELIZUMAB IN COMBINATION WITH ZANUBRUTINIB AND METHOTREXATE IS AN EFFECTIVE REGIMEN FOR PRIMARY CENTRAL NERVOUS SYSTEM DIFFUSE LARGE B CELL LYMPHOMA

EHA Library, Xia Zhao, 420185

BTG1 MUTATION CORRELATES WITH INFERIOR PROGNOSIS IN DIFFUSE LARGE B-CELL LYMPHOMA

EHA Library, Jin-Hua Liang, 420186

COMBINATION OF VENETOCLAX AND STANDARD PLATINUM-CONTAINING REGIMENS IN THE TREATMENT OF RELAPSES AND RESISTANT COURSE OF B-CELL LYMPHOMAS.

EHA Library, Lev Butaev, 420187

INTENSIVE THERAPY OF AGGRESSIVE B-CELL LYMPHOMAS WITH TP53 GENE MUTATION

EHA Library, Nelli Gabeeva, 420188

IPI 1-2 WITH BULKY DISEASE AND/OR VERY HIGH LDH IS A HIGH-RISK SUBGROUP OF UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): A HELLENIC DATABASE VALIDATION OF THE LEO COHORT

EHA Library, Theodoros Vassilakopoulos, 420189

VENETOCLAX AND BTK INHIBITORS BASED CHEMOTHERAPY IS A POTENTIAL EFFECTIVE CAR-T BRIDGING THERAPY IN R/R B-NHL

EHA Library, Liu Rui, 420190

INTENSIFIED R-CODOX-M/IVAC THERAPY FOR BIOLOGICALLY UNFAVOURABLE DIFFUSE LARGE B-CELL LYMPHOMA: EFFICACY, TOXICITY, AND CNS RELAPSE PREVENTION

EHA Library, Morgana Schirru, 420191

CHIDAMIDE WITH AZACITIDINE AND CHOP TREATMENT PLUS AUTO-ASCT FOR PATIENTS WITH NEWLY DIAGNOSED PERIPHERAL T-CELL LYMPHOMA:INTERIM ANALYSIS OF A PROSPECTIVE,SINGLE CENTER,SINGLE-ARM, PHASE 2 TRIAL

EHA Library, Chunyan Xiao, 420193

THE PREDICTIVE ROLE OF FIRST-LINE TREATMENT INTERIM PET IN PERIPHERAL T-CELL LYMPHOMA: A RETROSPECTIVE STUDY

EHA Library, Nicolò Rampi, 420194

COMPREHENSIVE GERIATRIC ASSESSMENT AS A PROGNOSTIC FACTOR FOR THE OUTCOME OF R-CHOP TREATMENT IN ELDERLY PATIENTS WITH AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMAS

EHA Library, Paula Jabłonowska-Babij, 420195

GEOGRAPHIC AND DEMOGRAPHIC DISTRIBUTION OF T-CELL AND NK-CELL LYMPHOMA ENTITIES IN PERU

EHA Library, Daniel Enriquez-Vera, 420196

BRUTON TYROSINE KINASE INHIBITORS AND CHIDAMIDE-COMBINED THERAPY IN RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA

EHA Library, Ping Li, 420197

CLINICAL AND RADIOLOGICAL FEATURES OF NEUROLOGICAL INVOLVEMENT IN INTRAVASCULAR LARGE B-CELL LYMPHOMA: A SINGLE-CENTER RETROSPECTIVE STUDY

EHA Library, Yi-ao Di, 420198

TISLELIZUMAB IN COMBINATION WITH GEMCITABINE, PEGASPARGAS, AND ETOPOSIDE (PPGE) IN PATIENTS WITH PRIMARY NK/T-CELL LYMPHOMA: A SINGLE-ARM, OPEN-LABEL, PHASE II STUDY

EHA Library, Chen Liu, 420199

PATHOGENIC GERMLINE CHEK2 VARIANTS IN LYMPHOID AND MYELOID NEOPLASMS

EHA Library, Adriana Oñós Clausell, 420200

CLINICAL FEATURES AND PROGNOSTIC FACTORS OF ADULT SYSTEMIC CHRONIC ACTIVE EPSTEIN-BARR VIRUS DISEASE: A RETROSPECTIVE ANALYSIS USING JAPANESE REGISTRY DATA

EHA Library, AIKA FUSEYA, 420201

EXPLORING THE PROGNOSTIC PERFORMANCE OF CIRCSCORE IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA

EHA Library, Ruth Salim, 420202

IDENTIFYING SOMATIC MUTATIONS IN AGGRESSIVE NON-HODGKIN B-CELL LYMPHOMA WITH ENHANCED SPECIFICITY USING LIQUID BIOPSY: A COMPARATIVE STUDY OF CELL-FREE DNA AND FFPE TISSUE

EHA Library, Gayaththri Vimalathas, 420203

FUNCTIONAL APOPTOSIS PROFILING REVEALS VULNERABILITIES IN T-CELL LARGE GRANULAR LYMPHOCYTIC LEUKEMIA

EHA Library, Paolo Mazzeo, 420204

SINGLE-CELL RNA SEQUENCING REVEALS MALIGNANT B CELL AND T CELL EXHAUSTION IN AIDS-RELATED DIFFUSE LARGE B CELL LYMPHOMA

EHA Library, Zailin Yang, 420205

POTENTIAL DIAGNOSTIC AND PROGNOSTIC BIOMARKERS OF PEDIATRIC BURKITT LYMPHOMA IDENTIFIED THROUGH MIRNA-SEQ OF TUMOR TISSUE AND PLASMA

EHA Library, Can Küçük, 420206

DRUG PROFILING IN A PRECLINICAL MURINE MANTLE CELL LYMPHOMA MOUSE MODEL IDENTIFIES NOVEL VULNERABILITIES

EHA Library, Luca Pagliaro, 420207

DECIPHERING THE BCR REPERTOIRE VIA 5′ RAPID AMPLIFICATION OF CDNA ENDS (5′RACE) IDENTIFIES PRIMARY MEDIASTINAL B-CELL LYMPHOMA CASES WITH HIGH TUMOR DENSITY AND POORER OUTCOMES

EHA Library, Vincent Camus, 420208

NON-CODING RNAS DRIVE IBRUTINIB RESISTANCE IN MANTLE CELL LYMPHOMA VIA THE AKT/PI3K AND MAPK PATHWAYS

EHA Library, Oshrat Hershkovitz-Rokah, 420209

RARE BUT SPECIFIC B-CELL RECEPTOR REACTIVITIES AGAINST COXSACKIEVIRUS A24 IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMAS

EHA Library, Igor Age Kos, 420210

INHIBITION OF NUCLEAR EXPORT PROMOTES EXPANDED NK CELL AND ANTI-CD19 CAR NK CELL LYSIS OF MALIGNANT B CELLS VIA DISRUPTION OF NKG2A

EHA Library, Jack Fisher, 420211

HISTONE LACTYLATION OF SFXN1 PROMOTER FACILITATES ONE-CARBON PATHWAY IN T-CELL LYMPHOMA

EHA Library, Xin Wang, 420212

GENOMIC PROFILING AND TRACKING OF CLASSICAL HODGKIN LYMPHOMA USING CELL-FREE DNA

EHA Library, Nick Veltmaat, 420213

RELATIONSHIP BETWEEN 18F-FDG PET/CT AND BIOLOGICAL CHARACTERIZATION OF PATIENTS WITH NON-HODGKIN LYMPHOMA UNDERGOING CAR THERAPY.

EHA Library, Luzalba Sanoja-Flores, 420214